{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 103 of 129', '13 References', '1. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and', 'other health and demographic factors: a US population-based study. J Allergy Clin', 'Immunol. 2013;132(5):1132-1138.', '2. Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A', 'population-based survey of eczema prevalence in the United States. Dermatitis.', '2007;18(2):82-91.', '3. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14) 1483-1494.', '4. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-1122', '5. Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, et al. Atopic dermatitis', 'is associated with a decrement in health-related quality of life. Int J Dermatol.', '2002;41(3):151-158', '6. Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in', 'lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459-464.', '7. Omori-Miyake M, Yamashita M, Tsunemi Y, Kawashima M, Yagi J. In vitro assessment of', 'IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice', 'and humans. J Invest Dermatol. 2014;134(5):1342-1350.', '8. Aleksza M, Luk\u00e1cs A, Antal-Szalm\u00e1s P, Hunyadi J, Szegedi A. Increased frequency of', 'intracellular interleukin (IL)-13 and IL-10, but not IL-4, expressing CD4+ and CD8+', 'peripheral T cells of patients with atopic dermatitis. Br J Dermatol.', '2002;147(6):1135-1141.', '9. Purwar R, Werfel T, Wittmann M. IL-13-stimulated human keratinocytes preferentially', 'attract CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Dermatol.', '2006;126(5):1043-1051.', '10. Oh MH, Oh SY, Lu J, Lou H, Myers AC, Zhu Z, Zheng T. TRPAA1-dependent pruritus in', 'IL-13-induced chronic atopic dermatitis. J Immunol. 2013;191(11):5371-5382.', '11. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of', 'interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest', 'Dermatol. 2009;129:742-751.', '12. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two', 'phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med.', '2016;375(24):2335-2348.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 104 of 129', '13. May RD, Monk PD, Cohen ES, Manuel D, Dempsey F, Davis NH, et al. Preclinical', 'development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe', 'uncontrolled asthma. Br J Pharmacol. 2012;166(1):177-193.', '14. Thom G, Minter R. Optimization of CAT-354, a therapeutic antibody directed against', 'interleukin-13, using ribosome display. Methods Mol Biol. 2012;805:393-401.', '15. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of', 'human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-', 'interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005;35(8):1096-1103.', '16. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for', 'treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol.', '2012;26(9):1176-1193.', '17. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al.', 'Guidelines of care for the management of atopic dermatitis: section 2. Management and', 'treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol.', '2014;71(1):116-132.', '18. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al.', 'Guidelines of care for the management of atopic dermatitis: section 3. Management and', 'treatment with phototherapy and systemic agents. J Am Acad Dermatol.', '2014;71(2):327-349.', '19. Bancroft AJ, Artis D, Donaldson DD, Sypek JP, Grencis RK. Gastrointestinal nematode', 'expulsion in IL-4 knockout mice is IL-13 dependent.', 'Eur J Immunol. 2000;30(7):2083-2091.', '20. Moffat GJ, Davies R, Kwon G, Retter MW, Chellman GJ, Kanapuram S, et al.', 'Investigation of maternal and fetal exposure to an IgG2 monoclonal antibody following', 'biweekly intravaginal administration to cynomolgus monkeys throughout pregnancy.', 'Reprod Toxicol. 2014;48:132-137.', '21. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol.', '1980;92(Suppl):44-47.', '22. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement:', 'updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}